Carl Spickett Academic Laboratory of Medical Genetics Academic - - PowerPoint PPT Presentation

▶
carl spickett academic laboratory of medical genetics
SMART_READER_LITE
LIVE PREVIEW

Carl Spickett Academic Laboratory of Medical Genetics Academic - - PowerPoint PPT Presentation

Feb 19, 2023 136 likes •454 views

Carl Spickett Academic Laboratory of Medical Genetics Academic Laboratory of Medical Genetics Academic Laboratory of Medical Genetics Academic Laboratory of Medical Genetics Human Karyotype Human Karyotype Human Karyotype Human Karyotype

slide-1
SLIDE 1

Carl Spickett

slide-2
SLIDE 2

Academic Laboratory of Medical Genetics Academic Laboratory of Medical Genetics Academic Laboratory of Medical Genetics Academic Laboratory of Medical Genetics

slide-3
SLIDE 3

Human Karyotype Human Karyotype Human Karyotype Human Karyotype

"NHGRI human karyotype" by Courtesy: National Human Genome Research Institute

slide-4
SLIDE 4

Genes to Proteins Genes to Proteins Genes to Proteins Genes to Proteins

slide-5
SLIDE 5

Von Hippel Von Hippel Von Hippel Von Hippel-

  • Lindau Disease

Lindau Disease Lindau Disease Lindau Disease

Rare inherited cancer syndrome named after Eugen Von Hippel and Arvid Lindau who described retinal angiomatosis and spinal haemangiobastomas respectively. Autosomal Dominant Inheritance from either parent Caused by VHL gene mutation on Chromosome 3 Loss of function of pVHL protein

slide-6
SLIDE 6

Von Hippel Lindau Disease Von Hippel Lindau Disease Von Hippel Lindau Disease Von Hippel Lindau Disease

Cerebella Haemangioblastoma Spinal Haemangioblastoma Adrenal gland Pheochromocytoma Renal Cysts and Renal Cell Carcinoma Retinal Angiomas Pancreatic Cysts

slide-7
SLIDE 7

HLRCC HLRCC HLRCC HLRCC

  • Hereditary Leiomyomatosis and Renal Cell Carcinoma
  • Rare kidney cancer susceptibility syndrome (Type 2 Papillary RCC)
  • Caused by mutations in FH gene encoding Fumerate Hydratase
  • Like VHL it is inherited in an autosomal dominant fashion
  • Benign growths present on skin (Leiomyomas)
slide-8
SLIDE 8

Tumour Suppressor Gene (TSG) Tumour Suppressor Gene (TSG) Tumour Suppressor Gene (TSG) Tumour Suppressor Gene (TSG)

Tumour suppressor Gene (TSG) Cell Cycle

Cell division (mitosis) Synthesis of new DNA Cell growth

slide-9
SLIDE 9

VHL VHL VHL VHL – – – – The story of a TSG The story of a TSG The story of a TSG The story of a TSG

  • L. Gossage et al., 2015. Nature Reviews Cancer
slide-10
SLIDE 10

VHL Tumour Suppressor Gene VHL Tumour Suppressor Gene VHL Tumour Suppressor Gene VHL Tumour Suppressor Gene

Adapted from: KEGG Pathways (clear-cell RCC)

slide-11
SLIDE 11

Kidney Cancer Kidney Cancer Kidney Cancer Kidney Cancer

  • Kidney cancers are eighth most common cancer type
  • RCC incidence has steadily increased in last 30 years
  • Early detection and removal CAN be curative, however poor prognosis

for metastatic disease. Targeted lethality of cells deficient in RCC gene function will enable advances in treatment for both inherited and sporadic RCC.

slide-12
SLIDE 12

Clear Cell Renal Cell Carcinoma ( Clear Cell Renal Cell Carcinoma ( Clear Cell Renal Cell Carcinoma ( Clear Cell Renal Cell Carcinoma (ccRCC ccRCC ccRCC ccRCC) ) ) )

  • Most common form of kidney cancer (~75 %)
  • Mutations in VHL TSG most common genetic event
  • Small fraction of RCC is accounted for by rare inherited monogenic disorders:
  • von Hippel-Lindau disease (VHL TSG encoding pVHL)
  • Birt-Hogg-Dubé syndrome (FLCN TSG encoding folliculin)
  • Hereditary leiomyomatosis renal cell cancer (HLRCC) (FH encoding fumerate hydratase)
  • Hereditary papillary RCC (MET proto-oncogene encoding hepatocyte growth factor receptor (HGFR))
  • Succinate dehydrogenase subunit disorders (SDHB, SDHD)
slide-13
SLIDE 13

Knudson’s ‘Two hit’ model Knudson’s ‘Two hit’ model Knudson’s ‘Two hit’ model Knudson’s ‘Two hit’ model

Familial mutation Sporadic cancer

slide-14
SLIDE 14

Clear Cell Renal Cell Carcinoma mutations Clear Cell Renal Cell Carcinoma mutations Clear Cell Renal Cell Carcinoma mutations Clear Cell Renal Cell Carcinoma mutations

Adapted from: Molecular Genetics of Clear-Cell Renal Cell Carcinoma. James Brugarolas. 2014.

10 20 30 40 50 60

VHL PBRM1 SETD2 BAP1 mTOR TCEB1 PIK3CA KDM5C TP53 PTEN

slide-15
SLIDE 15

Existing Therapies Existing Therapies Existing Therapies Existing Therapies

Treatment Type Target Kinase Inhibitors Sorafenib Multikinase Inhibitor Inhibitor of Ras signalling, VEGF receptors and PDGF receptors. Sunitinib Receptor tyrosine kinase (RTK) Inhibitor Inhibitor of VEGFR, PDGFR and c-Kit (CD117) signalling Axitinib and Tivozanib VEGFR Tyrosine kinase inhibitor Inhibits downstream targets of VEGFR Dovitinib Oral FGFR and VEGFR inhibitor Inhibits downstream targets of VEGFR and FGFR Pazopanib Oral Multikinase angiogenesis inhibitor Inhibits VEGFR, PDGFR and c-Kit signalling mTOR Inhibitors Temsirolimus mTOR inhibitor (stimulator of ribosomal translation of multiple mRNAs) mTOR inhibition decreases HIF1α translation Everolimus Oral mTOR inhibitor Used after failed treatment with Sorafenib or Sunitinib Antibodies Bavacizumab VEGF monoclonal antibody (in conjunction with IFNα) Targets and inactivates VEGF (HIF target) for treatment of advanced ccRCC. IFNα to increase immune response.

slide-16
SLIDE 16

Existing Therapies Existing Therapies Existing Therapies Existing Therapies

Adapted from: KEGG Pathways (clear-cell RCC)

Sorafenib Pazopanib Dovitanib Tivozanib Axitinib Sunitinib Temsirolimus Everolimus

Bavacizumab Kinase Inhibitors mTOR inhibitors

slide-17
SLIDE 17

Cell Lines Cell Lines Cell Lines Cell Lines

  • We have 21 cell lines at our disposal!
  • Cell lines with and without functional pVHL
  • Cells have been put through ‘Trusight cancer panel’ to check for cancer associated changes
  • Very useful for high-throughput assays and target identification
  • Cells in culture are relatively amenable to alteration
  • 1. Knock-down
  • 2. Knock-out
  • 3. Rescue
slide-18
SLIDE 18

Synthetic Lethality Synthetic Lethality Synthetic Lethality Synthetic Lethality

Synthetic lethality in cells not expressing pVHL Survival in cells stably transfected for VHL (rescue)

Beta-actin pVHL 25 kDa

slide-19
SLIDE 19

Cells in Culture Cells in Culture Cells in Culture Cells in Culture

slide-20
SLIDE 20

Cells in Culture Cells in Culture Cells in Culture Cells in Culture

slide-21
SLIDE 21

Cell Screening Cell Screening Cell Screening Cell Screening

slide-22
SLIDE 22

What Next? What Next? What Next? What Next?

0 hours 17 hours 24 hours

Wound healing ‘scratch assay’ Colony formation assays Cell migration assays

slide-23
SLIDE 23

3 3 3 3-

  • D Culture

D Culture D Culture D Culture

  • Cells appear to form spherical structures in 3D culture
  • These spheroids are organised ball-like shapes
  • Could be used as a qualitative indicator for cell dysfunction
  • Show effect of depletion of target protein on cell growth
slide-24
SLIDE 24
slide-25
SLIDE 25
slide-26
SLIDE 26
slide-27
SLIDE 27

Drug Development Drug Development Drug Development Drug Development

slide-28
SLIDE 28

Identification of Therapeutic Agents Identification of Therapeutic Agents Identification of Therapeutic Agents Identification of Therapeutic Agents

The ‘Pfizer Three Pillars’ Drug must be exposed at the target site Must bind pharmacological target as expected mode of action Must show pharmacological activity and illicit a response

slide-29
SLIDE 29

Summary Summary Summary Summary

Cell biology approach to target identification for drug development Challenging work which requires patience, persistence and positivity We are a long way from developing new treatments but we are working hard and forming important collaborations Realistic project aim is target identification and testing in animal disease models (mice and zebrafish)

slide-30
SLIDE 30

Thank you to: Group Leader Eamonn Maher Lab members France Docquier Hilda Mujcic Hannah West Phil Smith Benoit Lan-Leung Graeme Clarke Ezequiel Rodriquez Eguzkine Ochoa Ruth Casey James Whitworth